Why did RGLS report zero EPS for all quarters in 2024?

Regulus Therapeutics (RGLS) reported zero EPS for all quarters in 2024 due to a combination of factors:

1. High Research and Development Expenses: Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. The company's financial results are influenced by its significant investment in research and development (R&D) activities.
2. Clinical Trial Costs: The company's lead product candidate, farabursen, is in Phase 1b clinical development for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The costs associated with conducting clinical trials, including the Phase 1b Multiple-Ascending Dose (MAD) study, have a significant impact on the company's financial performance.

In summary, the reported zero EPS for all quarters in 2024 can be attributed to the high R&D expenses, including clinical trial costs, that the company incurs in its pursuit of developing innovative medicines.